Immunotherapy for Mesothelioma Gets Boost with Another Orphan Drug Status

Immunotherapy for Mesothelioma Gets Boost with Another Orphan Drug Status
Morphotek, Inc. was awarded Orphan Drug Status for amatuximab earlier this month, sending a ray of hope to early stage mesothelioma patients who are banking on immunotherapy in their battle to survive. Amatuximab (MORAb-009) is an investigational …

Full News here – Read more on Asbestos.com

Leave a Reply